MA29231B1 - Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques - Google Patents

Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques

Info

Publication number
MA29231B1
MA29231B1 MA30075A MA30075A MA29231B1 MA 29231 B1 MA29231 B1 MA 29231B1 MA 30075 A MA30075 A MA 30075A MA 30075 A MA30075 A MA 30075A MA 29231 B1 MA29231 B1 MA 29231B1
Authority
MA
Morocco
Prior art keywords
allergic
treatment
inflammatory
pharmaceutically acceptable
reperfusion injury
Prior art date
Application number
MA30075A
Other languages
English (en)
Inventor
Laxmikant Atmaram Gharat
Balasubramanian Gopalan
Neelima Khairatkar-Joshi
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of MA29231B1 publication Critical patent/MA29231B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DE NOUVEAUX INHIBITEURS DE LA PHOSPHODIESTÉRASE DE TYPE 4 (PDE4) DE FORMULE (1) AINSI QUE DES ANALOGUES, DES TAUTOMÈRES, DES ÉNANTIOMÈRES, DES DIASTÉROMÈRES, DES RÉGIOISOMÈRES, DES STÉRÉOISOMÈRES, DES POLYMORPHES, DES SELS PHARMACEUTIQUEMENT ACCEPTABLES, DES N-OXYDES APPROPRIÉS ET DES SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES DE CES COMPOSÉS. L'INVENTION CONCERNE ÉGALEMENT DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, CES COMPOSITIONS ÉTANT UTILES DANS LE TRAITEMENT DE MALADIES ALLERGIQUES ET INFLAMMATOIRES TELLES QUE L'ASTHME, LA BRONCHITE CHRONIQUE, LA DERMATITE ATOPIQUE, L'URTICAIRE, LA RHINITE ALLERGIQUE, LA CONJONCTIVITE ALLERGIQUE, LA CONJONCTIVITE PRINTANIÈRE, LE GRANULOME ÉOSINOPHILIQUE, LE PSORIASIS, L'ARTHRITE RHUMATOÏDE, LE CHOC SEPTIQUE, LA RECTOCOLITE HÉMORRAGIQUE, LA MALADIE DE CROHN, LA LÉSION DE REPERFUSION DU MYOCARDE ET LA LÉSION DE REPERFUSION DU CERVEAU, LA GLOMÉRULONÉPHRITE CHRONIQUE, LE CHOC ENDOTOXIQUE ET LE SYNDROME DE DÉTRESSE RESPIRATOIRE DE L'ADULTE.
MA30075A 2004-12-17 2007-07-12 Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques MA29231B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63723204P 2004-12-17 2004-12-17
IN1352MU2004 2004-12-17

Publications (1)

Publication Number Publication Date
MA29231B1 true MA29231B1 (fr) 2008-02-01

Family

ID=36384379

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30075A MA29231B1 (fr) 2004-12-17 2007-07-12 Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques

Country Status (18)

Country Link
US (1) US8129401B2 (fr)
EP (1) EP1831227B1 (fr)
JP (1) JP5122974B2 (fr)
KR (1) KR101317119B1 (fr)
AP (1) AP2334A (fr)
AR (1) AR066386A1 (fr)
AU (1) AU2005315319B2 (fr)
BR (1) BRPI0517211B8 (fr)
CA (1) CA2591438C (fr)
EA (1) EA014956B1 (fr)
IL (1) IL183827A (fr)
MA (1) MA29231B1 (fr)
MX (1) MX2007007345A (fr)
MY (1) MY143483A (fr)
NZ (1) NZ555809A (fr)
PL (1) PL1831227T3 (fr)
TW (1) TWI359814B (fr)
WO (1) WO2006064355A2 (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263648B2 (en) * 2006-09-11 2012-09-11 Mylan Laboratories Ltd. Diebenzofuran derivatives as inhibitors of PDE-4 and PDE-10
RU2334514C1 (ru) * 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2008081282A2 (fr) * 2006-12-20 2008-07-10 Glenmark Pharmaceuticals S.A. Procédé pour la synthèse de n9-(3,5-dichloro-4-pyridyl)-6- difluorométhoxybenzo(4,5)furo(3,2-c)pyridine-9-carboxamide et leurs sels
US20110160213A1 (en) * 2007-02-01 2011-06-30 Glenmark Pharmaceuticals, S.A. Pharmaceutical compositions for the treatment of inflammatory and allergic disorders
US8524905B2 (en) 2007-05-22 2013-09-03 Glenmark Pharmaceuticals S.A. Processes for preparing 6-(difluoromethoxy)[1]benzofuro[3,2-c]pyridine-9-carbaldehyde, a novel intermediate for the synthesis of PDE IV inhibitors
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP5544296B2 (ja) 2007-11-16 2014-07-09 ライジェル ファーマシューティカルズ， インコーポレイテッド 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物
ES2553340T3 (es) 2007-12-12 2015-12-07 Rigel Pharmaceuticals, Inc. Compuestos de carboxamida, sulfonamida y amina para trastornos metabólicos
EP2070913A1 (fr) 2007-12-14 2009-06-17 CHIESI FARMACEUTICI S.p.A. Dérivés d'ester en tant qu'inhibiteurs de la phosphodiestérase
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
MX2010011288A (es) 2008-04-23 2010-11-09 Rigel Pharmaceuticals Inc Compuestos de carboxamida para el tratamiento de trastornos metabolicos.
CA2758149A1 (fr) 2009-04-09 2010-10-14 Boehringer Ingelheim International Gmbh Inhibiteurs de la replication du vih
CN102480955B (zh) 2009-04-29 2015-08-05 梅迪维新技术公司 吡啶并[4,3-b]吲哚类和使用方法
CA2760516A1 (fr) 2009-04-29 2011-02-17 Medivation Technologies, Inc. Pyrido[4,3-b]indoles et leurs methodes d'utilisation
WO2011003007A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azabicycloalcane-indole et d’azabicycloalcane-pyrrolo-pyridine, procédés de préparation, et utilisation de ceux-ci
WO2011003005A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 d’azépino[b]indole et pyrido-pyrrolo-azépine azinone-substitué, procédés de préparation, et utilisation de ceux-ci
WO2011003012A1 (fr) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Antagonistes de mch-1 azapolycycles substitués par azinone, leurs procédés de fabrication et leur utilisation
US9073925B2 (en) 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
WO2011132051A2 (fr) * 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Composés tricycliques en tant qu'inhibiteurs de la phosphodiestérase-10
RU2417081C1 (ru) * 2010-05-07 2011-04-27 Ольга Филипповна Сибирева Способ лечения больных хроническим гломерулонефритом в сочетании с хроническим описторхозом
US8980905B2 (en) * 2010-06-24 2015-03-17 Leo Pharma A/S Benzodioxole or benzodioxepine heterocyclic compounds as phosphodiesterase inhibitors
WO2012088038A2 (fr) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Antagonistes de mch-1 consistant en tétrahydro-carbolines substituées par pipérazinone, leurs procédés de fabrication et utilisations
WO2012088124A2 (fr) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Antagonistes de la mch-1 à base de tétrahydro-azacarboline, leurs procédés de fabrication et leurs utilisations
WO2012098495A1 (fr) 2011-01-19 2012-07-26 Glenmark Pharmaceuticals Sa Composition pharmaceutique qui comprend le revamilast et un agoniste de bêta-2
CA2823955A1 (fr) 2011-01-19 2012-07-26 Albany Molecular Research, Inc. Benzofuro[3,2-c]pyridines et analogues associes en tant que modulateurs du sous-type 6 de la serotonine (5-ht6) pour traitement de l'obesite, du syndrome metabolique, de la cognition et de la schizophrenie
WO2012110946A1 (fr) 2011-02-17 2012-08-23 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant l'inhibiteur d'enzyme pde4 révamilast et un agent de modification pathologique, de préférence, le méthotrexate
US8791132B2 (en) 2011-02-18 2014-07-29 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012168907A1 (fr) 2011-06-10 2012-12-13 Glenmark Pharmaceuticals Sa Composition pharmaceutique comprenant du révamilast et du montélukast ou du zafirlukast
WO2013084182A1 (fr) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Composition pharmaceutique comprenant un inhibiteur de l'enzyme pde4 et un agent analgésique
US9783529B2 (en) 2013-03-13 2017-10-10 Flatley Discovery Lab, Llc Pyridazinone compounds and methods for the treatment of cystic fibrosis
UY35625A (es) 2013-06-25 2014-12-31 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa
CN105473573B (zh) 2013-06-25 2018-03-16 百时美施贵宝公司 用作激酶抑制剂的咔唑甲酰胺化合物
PT3461821T (pt) 2014-10-24 2020-08-05 Bristol Myers Squibb Co Compostos de indol carboxamida úteis como inibidores de quinase
CA2965516A1 (fr) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Composes atropisomeres tricycliques
TN2017000158A1 (en) 2014-10-24 2018-10-19 Bristol Myers Squibb Co Carbazole derivatives
CN106496322A (zh) * 2015-09-07 2017-03-15 江苏恒瑞医药股份有限公司 人胰岛素或其类似物的酰化衍生物的制备方法
JP6472428B2 (ja) * 2015-12-09 2019-02-20 財團法人食品工業發展研究所 キサンチンオキシダーゼ活性の阻害におけるβ−カルボリンアルカロイドの使用
CN112898376B (zh) * 2019-12-02 2022-06-24 首都医科大学 二氧六环修饰的四氢咔啉-3-甲酰-The-HGK,其制备,抗肿瘤活性和应用
CN112979667B (zh) * 2019-12-02 2022-04-22 首都医科大学 二氧六环修饰的四氢咔啉-3-甲酰-The,其合成,活性和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1041861A (en) 1962-03-14 1966-09-07 Organon Labor Ltd Pyrrolidone derivatives and pharmaceutical preparations containing them
US3759948A (en) 1969-06-25 1973-09-18 Merck & Co Inc Non-steroid anti-inflammatory compounds
NL7008628A (fr) 1969-06-25 1970-12-29
US3846553A (en) 1969-12-03 1974-11-05 Merck & Co Inc 3-substituted-2-pyridones in the treatment of pain, fever or inflammation
NL7016899A (fr) 1969-12-03 1971-06-07
US4222944A (en) 1978-07-31 1980-09-16 Hoffmann-La Roche Inc. Halo-3-dibenzofuran alkanonitriles
JPS62158253A (ja) 1985-12-28 1987-07-14 Kirin Brewery Co Ltd ４−アミノピリジンアミド誘導体
JPH0812430B2 (ja) 1986-07-07 1996-02-07 キヤノン株式会社 電子写真感光体
DE3779221D1 (de) 1986-08-19 1992-06-25 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und -zytokinen.
JPS63250378A (ja) * 1987-04-07 1988-10-18 Mitsubishi Kasei Corp インド−ル誘導体
US5202344A (en) 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
IE71647B1 (en) 1991-01-28 1997-02-26 Rhone Poulenc Rorer Ltd Benzamide derivatives
US5602173A (en) 1992-04-02 1997-02-11 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
EP0652868B1 (fr) 1992-07-28 2004-11-10 Aventis Pharma Limited Inhibiteurs de phosphodiesterase d'amp cyclique
MX9306311A (es) 1992-10-13 1994-04-29 Smithkline Beecham Plc Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9304920D0 (en) 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
CN1046939C (zh) 1993-07-02 1999-12-01 比克·古尔顿·劳姆贝尔格化学公司 氟烷氧基取代的苯甲酰胺类及其制备方法和应用
GB9315595D0 (en) 1993-07-28 1993-09-08 Res Inst Medicine Chem New compounds
WO1995009837A1 (fr) 1993-10-01 1995-04-13 Smithkline Beecham Corporation Composes cyano
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
GB9404706D0 (en) 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
WO1996003377A1 (fr) 1994-07-27 1996-02-08 Sankyo Company, Limited Composes heterocycliques utiles comme effecteurs allosteriques au niveau des recepteurs muscariniques
DE69637257T2 (de) 1995-04-14 2008-06-12 Smithkline Beecham Corp. Verfahren zur Herstellung eines Dosierinhalators
US6514996B2 (en) * 1995-05-19 2003-02-04 Kyowa Hakko Kogyo Co., Ltd. Derivatives of benzofuran or benzodioxole
DE19616573C2 (de) 1996-04-25 1999-03-04 Pari Gmbh Verwendung unterkritischer Treibmittelmischungen und Aerosole für die Mikronisierung von Arzneimitteln mit Hilfe dichter Gase
NZ333063A (en) 1996-09-04 2000-12-22 Warner Lambert Co Dibenzofuran sulfonamide derivatives as matrix metalloproteinase inhibitors
US6177440B1 (en) * 1996-10-30 2001-01-23 Eli Lilly And Company Substituted tricyclics
JP3530004B2 (ja) 1998-02-06 2004-05-24 株式会社日立ユニシアオートモティブ 吸入式投薬器
KR100898094B1 (ko) 1998-03-19 2009-05-18 버텍스 파마슈티칼스 인코포레이티드 카스파제의 억제제
US6110962A (en) 1998-05-12 2000-08-29 American Home Products Corporation 11-aryl-benzo[B]naphtho[2,3-D]furans and 11-aryl-benzo[B]naphtho[2,3-D]thiophenes useful in the treatment of insulin resistance and hyperglycemia
CA2330623A1 (fr) 1998-05-12 1999-11-18 Zenan Li 11-aryl-benzo[b]naphto[2,3-d]furanes et 11-aryl-benzo[b]naphto[2,3-d]thiophenes utiles dans les traitements de la resistance insulinique et de l'hyperglycemie
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
SK13072002A3 (sk) 2000-03-17 2003-08-05 Bristol-Myers Squibb Pharma Company Deriváty cyklických beta-aminokyselín ako inhibítory matrixových metaloproteáz a TNF-alfa
DE60125026T2 (de) 2000-03-23 2007-06-28 Takeda Pharmaceutical Co. Ltd. Fluorisochinolinderivate, verfahren zu ihrer herstellung und ihre anwendung
WO2002060867A2 (fr) 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Derives de carbazole et leur utilisation en tant qu'inhibiteurs d'heparanase
US20020128920A1 (en) 2001-03-06 2002-09-12 Dilip Chopra System and method for providing lowest costs purchasing
WO2002072567A2 (fr) 2001-03-13 2002-09-19 Glenmark Pharmaceuticals Limited Nouveaux composes heterocycliques utiles dans le traitement des troubles allergiques inflammatoires; procede de leur preparation et compositions pharmaceutiques les contenant
AU2003253130A1 (en) 2002-08-19 2004-03-03 Glenmark Pharmaceuticals Limited Condensed heterocyclic compounds as pde-iv inhibitors for the treatment of inflammatory and allergic disorders
WO2004022536A1 (fr) 2002-09-04 2004-03-18 Glenmark Pharmaceuticals Limited Nouveaux composes amides heterocycliques utilises pour le traitement d'affections inflammatoires et allergiques; procede permettant de les fabriquer et compositions pharmaceutiques les contenant
US7238725B2 (en) 2002-10-23 2007-07-03 Glenmark Pharmaceuticals Ltd. Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
WO2004069831A1 (fr) * 2003-02-10 2004-08-19 Glenmark Pharmaceuticals Ltd. Composes tricycliques utiles dans le traitement de troubles inflammatoires et allergiques, et procede de preparation de ces composes
PL378813A1 (pl) * 2003-04-11 2006-05-29 Glenmark Pharmaceuticals S.A. Nowe związki heterocykliczne przydatne w leczeniu stanów zapalnych i zaburzeń alergicznych: sposób ich wytwarzania i kompozycje farmaceutyczne zawierające te związki

Also Published As

Publication number Publication date
IL183827A0 (en) 2007-09-20
JP2008524201A (ja) 2008-07-10
MY143483A (en) 2011-05-31
AP2334A (en) 2011-12-06
AR066386A1 (es) 2009-08-19
CA2591438A1 (fr) 2006-06-22
AU2005315319B2 (en) 2011-07-07
PL1831227T3 (pl) 2013-10-31
HK1111147A1 (en) 2008-08-01
NZ555809A (en) 2010-07-30
MX2007007345A (es) 2007-09-07
EA014956B1 (ru) 2011-04-29
US20110190303A1 (en) 2011-08-04
EP1831227A2 (fr) 2007-09-12
US8129401B2 (en) 2012-03-06
BRPI0517211A (pt) 2008-09-30
EP1831227B1 (fr) 2013-06-19
WO2006064355A3 (fr) 2006-08-03
IL183827A (en) 2013-02-28
TWI359814B (en) 2012-03-11
CA2591438C (fr) 2014-04-29
KR20070100254A (ko) 2007-10-10
EA200701268A1 (ru) 2007-12-28
BRPI0517211B8 (pt) 2021-05-25
WO2006064355A2 (fr) 2006-06-22
AU2005315319A1 (en) 2006-06-22
TW200634015A (en) 2006-10-01
JP5122974B2 (ja) 2013-01-16
AP2007004031A0 (en) 2007-06-30
BRPI0517211B1 (pt) 2020-08-11
KR101317119B1 (ko) 2013-10-11

Similar Documents

Publication Publication Date Title
MA29231B1 (fr) Nouveaux composes heterocycliques utiles pour le traitement de troubles inflammatoires et allergiques
DE69008366T2 (de) 2-Aminopyrimidinon-Derivate.
MA27801A1 (fr) Nouveaux composes heterocycliques pour le traitement des affections inflammatoires et allergiques, leur procede de preparation et compositions pharmaceutiques les contenant
US5140029A (en) 2-aminopyrimidinone derivatives
SG155909A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
JP2002517445A (ja) ｃＧＭＰホスホジエステラーゼのキナゾリノン抑制剤
SG155943A1 (en) Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors
WO2000047558A1 (fr) Composes amide et leur utilisation medicinale
WO2008157740A2 (fr) Inhibiteurs de faah
MX2008011369A (es) Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2.
EP2411009B1 (fr) Applications thérapeutiques de dérivés de quinazolinedione
AU2007235132A1 (en) Quinolones useful as inducible nitric oxide synthase inhibitors
TNSN07098A1 (en) 2,6- substituted -4- monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
CN102686580A (zh) 用作酪蛋白激酶抑制剂的咪唑衍生物
CN1434817A (zh) 吡唑环腺苷酸－特异性磷酸二酯酶抑制剂
NO20073436L (no) Nye heterosykliske forbindelser nyttige for behandling av inflammatoriske og allergiske forstyrrelser
WO2010116090A1 (fr) Applications thérapeutiques dans le domaine cardiovasculaire de dérivés de quinazolinedione
US5026853A (en) 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide
CN101563337A (zh) 吲哚化合物
KR20170139074A (ko) Pde10 억제제 및 관련 조성물 및 방법
JP2003176273A (ja) アミド化合物およびその医薬としての用途
US5196425A (en) Antihypertensive 3-piperidinyl-indazole derivatives
US5321028A (en) Antihypertensive 3-piperidinyl-indazole derivatives
US5284854A (en) 2-aminopyrimidinone derivatives